Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer. (February 2015)

• Record Type: Journal Article
• Authors: Safran, Howard; Charpentier, Kevin P.; Kaubisch, Andreas; Mantripragada, Kalyan; Dubel, Gregory; Perez, Kimberly; Faricy-Anderson, Katherine; Miner, Thomas; Eng, Yoko; Victor, Joel; Plette, Angela; Espat, Joseph; Bakalarski, Pamela; Wingate, Patti; Berz, David; Luppe, Denise; Martel, Diane; Rosati, Kayla; Aparo, Santiago
• Is Part Of: American journal of clinical oncology. Volume 38:Number 1(2015)
• Publication Date: 2015-02
• Subjects: Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0b013e3182868c66
• Languages: English
• ISSNs: 0277-3732

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Purpose:</title> <p>To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib.</p> </sec> <sec> <title>Materials and Methods:</title> <p>Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities.</p> </sec> <sec> <title>Results:</title> <p>Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months.</p> </sec> <sec> <title>Conclusions:</title> <p>Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.</p> </sec> </abstract>